RCUSArcus Biosciences, Inc.Finished
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Metastatic Colorectal Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 227 (final count)
- Started
- May 10, 2021
- Main results expected
- Sep 5, 2025
- Fully finished
- Sep 5, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort A and B - Progression-free Survival (PFS)
Measured over: From randomization until death from any cause (up to approximately 3-7 years)
Cohort C - Objective Response Rate (ORR)
Measured over: From randomization until death from any cause (up to approximately 3-7 years)
Number of Participants With Treatment-emergent Adverse Events
Measured over: Up to approximately 10 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-09-05, no fading
Raw record changes
- none yet
Trial ID NCT04660812 · record last updated 2025-10-20 · checked 2026-11-09 15:47 UTC